Product Name
Tafazzin (TAZ), Recombinant Protein
Popular Item
Full Product Name
Recombinant Tafazzin (TAZ)
Product Gene Name
TAZ recombinant protein
[Similar Products]
Matching Pairs
Unconjugated
Antibody: Tafazzin (TAZ) (MBS2006693)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Matching Pairs
APC-CY7 Conjugated Antibody: Tafazzin (TAZ) (MBS2074616)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Matching Pairs
PE Conjugated Antibody: Tafazzin (TAZ) (MBS2074617)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Matching Pairs
APC Conjugated Antibody: Tafazzin (TAZ) (MBS2074618)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Matching Pairs
Cy3 Conjugated Antibody: Tafazzin (TAZ) (MBS2074619)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Matching Pairs
FITC Conjugated Antibody: Tafazzin (TAZ) (MBS2074620)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Matching Pairs
HRP Conjugated Antibody: Tafazzin (TAZ) (MBS2074621)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Matching Pairs
Biotin Conjugated Antibody: Tafazzin (TAZ) (MBS2095740)
Immunogen: Tafazzin (TAZ) (MBS2011264)
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
MBS2011264 Technical Datasheet
Technical Datasheet PDF
Chromosome Location
Chromosome: 1; NC_005100.3 (152161153..152169569, complement). Location: chromosome: 1
3D Structure
ModBase 3D Structure for Q4KLG6
Concentration
Original Concentration: 200 ug/mL (lot specific)
Organism Species
Rattus norvegicus (Rat)
Source
Prokaryotic expression
Traits
Freeze-dried powder
Buffer formulation
20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT,0.01% SKL, 5% Trehalose and Proclin300.
Predicted isoelectric point
9.0
Predicted Molecular Mass
26.1kDa
Accurate Molecular Mass
27kDa as determined by SDS-PAGE reducing conditions.
Usage
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not
vortex.
Preparation and Storage
Storage: Avoid repeated freeze/thaw cycles.
Store at 2-8oC for one month.
Aliquot and store at -80oC for 12 months.
Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
ISO Certification
Manufactured in an ISO 9001:2008 and ISO 13485:2003 Certified Laboratory.
Supply Chain Verification
Manufactured in a lab with traceable raw materials. Bulk orders can typically be prepared to the customera??s specifications, please inquire.
Other Notes
Small volumes of TAZ recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for TAZ recombinant protein
Positive Control; Immunogen; SDS-PAGE; WB.
(May be suitable for use in other assays to be determined by the end user.)
Sequence Information of TAZ recombinant protein
SDS-Page of TAZ recombinant protein
NCBI/Uniprot data below describe general gene information for TAZ. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001020919.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001025748.1
[Other Products]
UniProt Primary Accession #
Q4KLG6
[Other Products]
NCBI Official Full Name
tafazzin
NCBI Official Synonym Full Names
tafazzin
NCBI Official Symbol
Taz??[Similar Products]
NCBI Protein Information
tafazzin; Barth syndrome); endocardial fibroelastosis 2; tafazzin (cardiomyopathy, dilated 3A (X-linked); tafazzin (cardiomyopathy, dilated 3A (X-linked); endocardial fibroelastosis 2; Barth syndrome)
UniProt Protein Name
Protein Taz
UniProt Gene Name
Taz??[Similar Products]
UniProt Synonym Gene Names
Taz_mapped??[Similar Products]
UniProt Entry Name
Q4KLG6_RAT
NCBI Summary for TAZ
human homolog may play a role in cardiolipin metabolism [RGD, Feb 2006]
UniProt Comments for TAZ
tafazzin: Some isoforms may be involved in cardiolipin (CL) metabolism. Defects in TAZ are the cause of Barth syndrome (BTHS). An X-linked disease characterized by dilated cardiomyopathy with endocardial fibroelastosis, a predominantly proximal skeletal myopathy, growth retardation, neutropenia, and organic aciduria, particularly excess of 3-methylglutaconic acid. Additional features include hypertrophic cardiomyopathy, isolated left ventricular non-compaction, ventricular arrhythmia, motor delay, poor appetite, fatigue and exercise intolerance, hypoglycemia, lactic acidosis, hyperammonemia, and dramatic late catch-up growth after growth delay throughout childhood. Belongs to the taffazin family. 9 isoforms of the human protein are produced by alternative splicing.
Protein type: Mitochondrial; Transferase; Membrane protein, integral
Cellular Component: membrane; mitochondrion; mitochondrial membrane; intrinsic to membrane; cytosol; nucleus
Molecular Function: 1-acylglycerophosphocholine O-acyltransferase activity; O-acyltransferase activity
Biological Process: inner mitochondrial membrane organization and biogenesis; cardiolipin biosynthetic process; cardiac muscle development; mitochondrial respiratory chain complex I assembly; skeletal muscle development; muscle contraction; cristae formation; heart development; hemopoiesis; organelle ATP synthesis coupled electron transport; cardiac muscle contraction
Research Articles on TAZ
1. Tafazzin knockdown interrupts the neonatal ventricular fibroblast cell cycle and this in turn may contribute to fibrosis and dilated cardiomyopathy in Barth syndrome.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.